<DOC>
	<DOCNO>NCT02293980</DOCNO>
	<brief_summary>PART 1 : The primary objective study identify maximum tolerate dose ( MTD ) PT2385 Tablets and/or recommend Phase 2 dose ( RP2D ) PT2385 Tablets patient advance clear cell renal cell carcinoma ( ccRCC ) . PART 2 : The primary objective study identify MTD PT2385 Tablets RP2D , combination nivolumab , patient advance ccRCC . PART 3 : The primary objective study identify MTD PT2385 Tablets RP2D , combination cabozantinib tablet , patient advance ccRCC .</brief_summary>
	<brief_title>A Phase 1 , Dose-Escalation Trial PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma</brief_title>
	<detailed_description>PART 1 : This Phase 1 , multiple-dose , dose-escalation trial PT2385 Tablets , patient advance ccRCC assign sequential dose cohort . Patient safety monitor frequent physical examination , vital sign measurement , electrocardiogram ( ECGs ) , hematology chemistry laboratory study , record adverse event ( AEs ) . Blood obtain analysis concentration PT2385 ass biomarkers . PART 2 : This Phase 1 trial PT2385 Tablets combination nivolumab , patient advance ccRCC assign dose cohort . Patient safety monitor frequent physical examination , vital sign measurement , ECGs , hematology chemistry laboratory study , record AEs . Blood obtain analysis concentration PT2385 ass biomarkers . PART 3 : This Phase 1 trial PT2385 Tablets combination cabozantinib tablet , patient advance ccRCC assign dose cohort . Patient safety monitor frequent physical examination , vital sign measurement , ECGs , hematology chemistry laboratory study , record AEs . Blood obtain analysis concentration PT2385 cabozantinb ass biomarkers .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>Inclusion Criteria PART 1 Has locally advance metastatic ccRCC progress treatment least one prior therapeutic regimen Is age ≥ 18 year Has life expectancy ≥ 3 month Has adequate organ function If female patient , must surgically sterile , postmenopausal , must agree use physicianapproved method birth control study minimum 30 day last study drug administration , male patient female partner , must agree use physicianapproved method birth control study minimum 30 day last study drug administration Able swallow oral medication PART 2 In addition PART 1 Received three prior systemic treatment regimen advance metastatic setting Must receive least one two prior antiangiogenic therapy regimens PART 3 In addition PART 1 • Must receive least one vascular endothelial growth factor receptor ( VEGFR ) target tyrosine kinase inhibitor Exclusion Criteria PART 1 Has history untreated brain metastasis history leptomeningeal disease spinal cord compression Has fail recover reversible effect prior anticancer therapy Has uncontrolled poorly control hypertension Is receive warfarin anticoagulant therapy expect require warfarin Has major cardiovascular event within 6 month prior study drug administration Has clinically significant cardiac , respiratory , medical psychiatric condition might interfere participation trial interfere interpretation trial result Has major surgery within 4 week first study drug administration Has know HIV Has active infection require systemic treatment Is participate another therapeutic clinical trial PART 2 In addition PART 1 Has history current CNS metastases Has receive prior immunotherapy Has active recent history know suspect autoimmune disease PART 3 In addition PART 1 Gastrointestinal ( GI ) disorder Any history congenital long QT syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>